Security Snapshot

INOVIO PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (INO) Institutional Ownership

CUSIP: 45773H409

13F Institutional Holders and Ownership History from Q4 2023 to Q2 2026

Latest Period

Q2 2026

Institutions Reporting

101

Shares (Excl. Options)

32,809,880

Price

$1.10

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
-391,196
Value change
-$1,703,197
Number of holders
101
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
85,714,275
SEC-reported price per share
$0.90
Insider filing price
$0.90
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • INO - INOVIO PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share is tracked under CUSIP 45773H409.
  • 101 institutions reported positions in Q2 2026.
  • 11 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 98 to 101 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from $54,590,692 to $36,119,687.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 101 institutions filings for Q2 2026.

Open SEC evidence

Security key

45773H409

Latest holder period

Q2 2026

13F holders

101

13D/G owners

11

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
11
Security
INO
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 9.9% $12,373,167 10,666,523 RA Capital Management, L.P. 31 Jul 2026
FMR LLC 10% -23% $9,807,565 -$1,026,388 8,454,797 -9.5% FMR LLC 30 Jun 2026
JANUS HENDERSON GROUP PLC 10% +63% $12,999,275 +$6,630,068 6,666,295 +104% JANUS HENDERSON GROUP PLC 28 Nov 2025
HIGHBRIDGE CAPITAL MANAGEMENT LLC 8.2% -11% $6,995,237 +$2,889,570 6,190,475 +70% HIGHBRIDGE CAPITAL MANAGEMENT LLC 31 Mar 2026
VANGUARD CAPITAL MANAGEMENT LLC 5% $4,827,417 4,161,566 Vanguard Capital Management 30 Jun 2026
Alyeska Investment Group, L.P. 6% -19% $6,400,000 4,000,000 0% Alyeska Investment Group, L.P. 31 Dec 2025
Adage Capital Management, L.P. 4% -31% $3,977,142 -$933,751 3,428,571 -19% Adage Capital Management, L.P. 30 Jun 2026
VANGUARD GROUP INC 5% -9.5% $5,769,107 +$2,238,719 3,315,579 +63% The Vanguard Group 31 Dec 2025
Stonepine Capital Management, LLC 3.8% -28% $2,683,444 -$900,721 1,434,997 -25% Stonepine Capital Management, LLC 31 Mar 2025
Deep Track Capital, LP 2.4% $3,076,623 1,314,796 Deep Track Capital, LP 30 Sep 2025
BlackRock, Inc. 1.5% -80% $1,099,608 -$3,642,379 537,627 -77% BlackRock, Inc. 30 Jun 2025

As of 30 Jun 2026, 101 institutional investors reported holding 32,809,880 shares of INOVIO PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (INO). This represents 38% of the company’s total 85,714,275 outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
37%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FMR LLC 9.9% 8,454,797 -9.5% 0% $9,300,277
Jupiter Topco LLC 6% 5,171,053 0% 0% $5,714,014
VANGUARD CAPITAL MANAGEMENT LLC 4.3% 3,650,562 +26% 0% $4,015,618
Boxer Capital Management, LLC 3.3% 2,844,994 +20% 0.24% $3,129,493
ADAR1 Capital Management, LLC 2.5% 2,143,910 +46% 0.11% $2,358,301
D. E. Shaw & Co., Inc. 1.6% 1,351,656 -39% 0% $1,486,822
TWO SIGMA INVESTMENTS, LP 1.4% 1,239,778 +218% 0% $1,363,756
Eversept Partners, LP 1.2% 1,035,360 0% 0.06% $1,138,896
GEODE CAPITAL MANAGEMENT, LLC 0.94% 802,751 +0.16% 0% $883,749
MILLENNIUM MANAGEMENT LLC 0.93% 796,107 -44% 0% $875,718
BlackRock, Inc. 0.91% 779,057 +18% 0% $856,963
VANGUARD FIDUCIARY TRUST CO 0.56% 480,769 +23% 0% $528,846
Caption Management, LLC 0.56% 478,950 0.02% $526,845
RENAISSANCE TECHNOLOGIES LLC 0.42% 361,339 -44% 0% $397,473
STATE STREET CORP 0.39% 336,610 +14% 0% $370,271
GSA CAPITAL PARTNERS LLP 0.31% 265,011 -0.02% 0.02% $292,000
UBS Group AG 0.31% 262,320 +5.1% 0% $288,552
Quadrature Capital Ltd 0.3% 258,928 0% $284,821
CITADEL ADVISORS LLC 0.28% 241,775 -16% 0% $265,952
NORTHERN TRUST CORP 0.2% 174,394 -42% 0% $191,833
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.2% 173,000 0% 0% $190,300
NOMURA HOLDINGS INC 0.18% 150,000 0% $165,000
HRT FINANCIAL LP 0.16% 140,432 +987% 0% $154,000
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main 0.16% 133,648 0% $147,012
GMT Capital Corp 0.15% 126,119 0% 0.01% $138,731

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
11
Latest
Q2 2026
Rows shown
1-11 of 11
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q2 32,809,880 $36,119,687 -$1,703,197 $1.10 101
2026 Q1 31,364,859 $54,590,692 -$2,795,850 $1.74 98
2025 Q4 33,075,777 $57,545,745 +$21,224,322 $1.74 100
2025 Q3 20,711,886 $48,449,935 +$25,433,512 $2.34 98
2025 Q2 10,168,502 $20,694,831 -$6,577,397 $2.04 101
2025 Q1 13,600,161 $22,159,691 +$51,992 $1.63 105
2024 Q4 13,346,624 $24,424,740 +$7,463,553 $1.83 100
2024 Q3 8,566,045 $49,511,575 +$2,096,827 $5.78 95
2024 Q2 8,056,972 $65,100,837 +$29,640,224 $8.08 92
2024 Q1 4,044,287 $56,123,192 +$53,680,856 $13.88 83
2023 Q4 298,900 $152,940 +$152,930 $0.51 7
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .